Bone and lymph node metastases from neuroblastoma detected by 18F-DOPA-PET/CT and confirmed by posttherapy 131I-MIBG but negative on diagnostic 123I-MIBG scan

Arnoldo Piccardo, Egesta Lopci, Massimo Conte, Manlio Cabria, Angelina Cistaro, Alberto Garaventa, Giampiero Villavecchia

Research output: Contribution to journalArticle

Abstract

We report the case of a 6-year-old child with stage 4 neuroblastoma, previously treated with chemotherapy, which relapsed in the right mandibular branch, right submandibular lymph nodes, and bone marrow. These sites of recurrence were detected on diagnostic I-MIBG and confirmed by F-DOPA-PET/CT, which revealed the following 2 additional sites of disease: in the skull base and the left supraclavicular lymph nodes. The patient was scheduled for radioiodine therapy and received a total dose of 7400 MBq (200 mCi) of I-MIBG. The whole-body scan, acquired 72 hours later, revealed all sites of disease detected by F-DOPA-PET/CT, including those negative on I-MIBG scan.

Original languageEnglish
JournalClinical Nuclear Medicine
DOIs
Publication statusAccepted/In press - Apr 10 2013

Fingerprint

3-Iodobenzylguanidine
Neuroblastoma
Lymph Nodes
Neoplasm Metastasis
Bone and Bones
Whole Body Imaging
Skull Base
Bone Marrow
Recurrence
Drug Therapy
Therapeutics

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

@article{1a3b13edbad440b8922c666d968d282a,
title = "Bone and lymph node metastases from neuroblastoma detected by 18F-DOPA-PET/CT and confirmed by posttherapy 131I-MIBG but negative on diagnostic 123I-MIBG scan",
abstract = "We report the case of a 6-year-old child with stage 4 neuroblastoma, previously treated with chemotherapy, which relapsed in the right mandibular branch, right submandibular lymph nodes, and bone marrow. These sites of recurrence were detected on diagnostic I-MIBG and confirmed by F-DOPA-PET/CT, which revealed the following 2 additional sites of disease: in the skull base and the left supraclavicular lymph nodes. The patient was scheduled for radioiodine therapy and received a total dose of 7400 MBq (200 mCi) of I-MIBG. The whole-body scan, acquired 72 hours later, revealed all sites of disease detected by F-DOPA-PET/CT, including those negative on I-MIBG scan.",
author = "Arnoldo Piccardo and Egesta Lopci and Massimo Conte and Manlio Cabria and Angelina Cistaro and Alberto Garaventa and Giampiero Villavecchia",
year = "2013",
month = "4",
day = "10",
doi = "10.1097/RLU.0b013e31827a0002",
language = "English",
journal = "Clinical Nuclear Medicine",
issn = "0363-9762",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Bone and lymph node metastases from neuroblastoma detected by 18F-DOPA-PET/CT and confirmed by posttherapy 131I-MIBG but negative on diagnostic 123I-MIBG scan

AU - Piccardo, Arnoldo

AU - Lopci, Egesta

AU - Conte, Massimo

AU - Cabria, Manlio

AU - Cistaro, Angelina

AU - Garaventa, Alberto

AU - Villavecchia, Giampiero

PY - 2013/4/10

Y1 - 2013/4/10

N2 - We report the case of a 6-year-old child with stage 4 neuroblastoma, previously treated with chemotherapy, which relapsed in the right mandibular branch, right submandibular lymph nodes, and bone marrow. These sites of recurrence were detected on diagnostic I-MIBG and confirmed by F-DOPA-PET/CT, which revealed the following 2 additional sites of disease: in the skull base and the left supraclavicular lymph nodes. The patient was scheduled for radioiodine therapy and received a total dose of 7400 MBq (200 mCi) of I-MIBG. The whole-body scan, acquired 72 hours later, revealed all sites of disease detected by F-DOPA-PET/CT, including those negative on I-MIBG scan.

AB - We report the case of a 6-year-old child with stage 4 neuroblastoma, previously treated with chemotherapy, which relapsed in the right mandibular branch, right submandibular lymph nodes, and bone marrow. These sites of recurrence were detected on diagnostic I-MIBG and confirmed by F-DOPA-PET/CT, which revealed the following 2 additional sites of disease: in the skull base and the left supraclavicular lymph nodes. The patient was scheduled for radioiodine therapy and received a total dose of 7400 MBq (200 mCi) of I-MIBG. The whole-body scan, acquired 72 hours later, revealed all sites of disease detected by F-DOPA-PET/CT, including those negative on I-MIBG scan.

UR - http://www.scopus.com/inward/record.url?scp=84875941437&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875941437&partnerID=8YFLogxK

U2 - 10.1097/RLU.0b013e31827a0002

DO - 10.1097/RLU.0b013e31827a0002

M3 - Article

JO - Clinical Nuclear Medicine

JF - Clinical Nuclear Medicine

SN - 0363-9762

ER -